Mutation of <i>rearranged during transfection (RET)</i> is associated with enhanced tumor immunogenicity and favorable outcomes in pan-cancer immunotherapy
Rearranged during transfection mutation may enhance anti-tumor immunity and function as an independent biomarker for promising outcomes across multiple cancer types treated with ICB. These findings have the potential to inform clinical decision-making, guide personalized immunotherapy strategies, and contribute to the advancement of precision oncology.
Authors
- Hongyun Zhao (ORCID: https://orcid.org/0000-0002-1251-3888)
- Jin Zhou (ORCID: https://orcid.org/0000-0002-5534-1123)
- Jingshuang Cai
- Yingying Li (ORCID: https://orcid.org/0000-0003-3243-1975)
- Bin Zhao (ORCID: https://orcid.org/0000-0001-6607-4182)
- Mingzhen Cai
- Yingzhi Xu
- Zhiyang Huang
Institutions
- Fujian Medical University (CN)
- Sun Yat-sen University (CN)
- Fifth Affiliated Hospital of Sun Yat-sen University (CN)
- Second Affiliated Hospital of Fujian Medical University (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-02-14
- DOI
- https://doi.org/10.1093/oncolo/oyag049
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00